My other question is about CETA as well. Regarding the protection of patents for pharmaceutical products, the technical summary of the Canada–EU CETA stipulates that Canada's federal government is prepared to address incremental cost impacts if concessions to the EU in this area have a financial impact on provinces or territories.
How would incremental cost impacts be assessed, and by whom?